Corbus Pharmaceuticals Holdings
Market Cap
US$608.2m
Last Updated
2020/07/02 00:05 UTC
Data Sources
Company Financials +
Executive Summary
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Mediocre balance sheet with limited growth.
Share Price & News
How has Corbus Pharmaceuticals Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRBP's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.7%
CRBP
1.4%
US Biotechs
1.9%
US Market
1 Year Return
22.3%
CRBP
22.0%
US Biotechs
4.3%
US Market
Return vs Industry: CRBP matched the US Biotechs industry which returned 22% over the past year.
Return vs Market: CRBP exceeded the US Market which returned 4.3% over the past year.
Shareholder returns
| CRBP | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.7% | 1.4% | 1.9% |
| 30 Day | 19.0% | 4.9% | 2.7% |
| 90 Day | 71.6% | 29.6% | 26.4% |
| 1 Year | 22.3%22.3% | 23.2%22.0% | 6.5%4.3% |
| 3 Year | 34.2%34.2% | 30.7%26.4% | 35.1%26.2% |
| 5 Year | 179.7%179.7% | 1.8%-4.2% | 67.0%48.4% |
Price Volatility Vs. Market
How volatile is Corbus Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?1 month ago | Simply Wall St
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Is Expected To BreakevenValuation
Is Corbus Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?
26.8x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CRBP ($8.39) is trading above our estimate of fair value ($1.53)
Significantly Below Fair Value: CRBP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRBP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CRBP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRBP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRBP is overvalued based on its PB Ratio (26.8x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Corbus Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
73.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRBP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRBP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRBP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRBP's revenue (73.3% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CRBP's revenue (73.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRBP's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Corbus Pharmaceuticals Holdings performed over the past 5 years?
-43.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRBP is currently unprofitable.
Growing Profit Margin: CRBP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRBP is unprofitable, and losses have increased over the past 5 years at a rate of -43.8% per year.
Accelerating Growth: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: CRBP has a negative Return on Equity (-329.97%), as it is currently unprofitable.
Next Steps
Financial Health
How is Corbus Pharmaceuticals Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: CRBP's short term assets ($54.7M) exceed its short term liabilities ($34.7M).
Long Term Liabilities: CRBP's short term assets ($54.7M) exceed its long term liabilities ($7.9M).
Debt to Equity History and Analysis
Debt Level: CRBP's debt to equity ratio (1.9%) is considered satisfactory.
Reducing Debt: CRBP's debt to equity ratio has increased from 1.5% to 1.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRBP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CRBP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 46.4% each year
Next Steps
Dividend
What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRBP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRBP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRBP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.7yrs
Average management tenure
CEO
Yuval Cohen (45yo)
6.25yrs
Tenure
US$4,001,509
Compensation
Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc ...
CEO Compensation Analysis
Compensation vs Market: Yuval's total compensation ($USD4.00M) is about average for companies of similar size in the US market ($USD3.11M).
Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.25yrs | US$4.00m | 0.098% $596.5k | |
| Chief Financial Officer | 6.25yrs | US$1.62m | 0.48% $2.9m | |
| Head of Research & Chief Medical Officer | 5.92yrs | US$1.67m | 0.28% $1.7m | |
| Chief Operating Officer | 0.92yr | no data | 0.049% $297.8k | |
| Senior Director of Investor Relations & Communications | no data | no data | no data | |
| Co-Founder & Consultant | 1.25yrs | US$1.66m | 2.91% $17.7m | |
| Senior Director & Head of Clinical Operations | no data | no data | no data | |
| Chief Commercial Officer | 1.42yrs | no data | 0.017% $100.7k | |
| Executive Director of Research | no data | no data | no data |
3.7yrs
Average Tenure
59yo
Average Age
Experienced Management: CRBP's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.25yrs | US$4.00m | 0.098% $596.5k | |
| Independent Director | 5.92yrs | US$243.12k | 0.065% $394.4k | |
| Director | 6.58yrs | US$235.62k | 0.97% $5.9m | |
| Independent Chairman | 6.25yrs | US$273.12k | 0.031% $188.8k | |
| Member of Scientific Advisory Board | 5.17yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.83yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.08yrs | US$220.62k | 0.0014% $8.4k | |
| Independent Director | 1.25yrs | US$606.34k | 0.00037% $2.3k | |
| Independent Director | 0.33yr | no data | no data |
5.2yrs
Average Tenure
52yo
Average Age
Experienced Board: CRBP's board of directors are considered experienced (5.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
Top Shareholders
Company Information
Corbus Pharmaceuticals Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Corbus Pharmaceuticals Holdings, Inc.
- Ticker: CRBP
- Exchange: NasdaqGM
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$608.195m
- Shares outstanding: 72.49m
- Website: https://www.corbuspharma.com
Number of Employees
Location
- Corbus Pharmaceuticals Holdings, Inc.
- 500 River Ridge Drive
- Norwood
- Massachusetts
- 2062
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRBP | NasdaqGM (Nasdaq Global Market) | Yes | New Common Shares | US | USD | Oct 2014 |
| 337 | DB (Deutsche Boerse AG) | Yes | New Common Shares | DE | EUR | Oct 2014 |
| 0SZI | LSE (London Stock Exchange) | Yes | New Common Shares | GB | USD | Oct 2014 |
Biography
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/02 00:05 |
| End of Day Share Price | 2020/07/01 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.